Ruth B. Thornton

17 Monash Avenue
Nedlands, WA 6009, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

A profile of abandoned fetal and neonatal remains admitted to the Diepkloof forensic pathology service medico-legal mortuary during the COVID-19 and post-COVID-19 periods.

A profile of abandoned fetal and neonatal remains admitted to the Diepkloof forensic pathology service medico-legal mortuary during the COVID-19 and post-COVID-19 periods.

Journal: International journal of injury control and safety promotion

Published: July 09, 2026

Mucosal immune cell priming by intranasally delivered Haemophilus haemolyticus is associated with heterologous protection against influenza and nontypeable Haemophilus influenzae.

Mucosal immune cell priming by intranasally delivered Haemophilus haemolyticus is associated with heterologous protection against influenza and nontypeable Haemophilus influenzae.

Journal: Frontiers in immunology

Published: April 14, 2026

The platform trial in COVID-19 priming and BOOsting (PICOBOO): The reactogenicity of nine licensed COVID-19 vaccines delivered in immunocompetent adults.

The platform trial in COVID-19 priming and BOOsting (PICOBOO): The reactogenicity of nine licensed COVID-19 vaccines delivered in immunocompetent adults.

Journal: Vaccine

Published: March 26, 2026

SARS-CoV-2 Ancestral and Omicron variant immunity in Australian children in 2023, a seroprevalence study.

SARS-CoV-2 Ancestral and Omicron variant immunity in Australian children in 2023, a seroprevalence study.

Journal: Vaccine

Published: February 08, 2026

The Platform trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters in immunocompetent adults.

The Platform trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters in immunocompetent adults.

Journal: Vaccine

Published: December 14, 2025

Evaluating the impact of the 'Blow, Breathe, Cough' health promotion intervention in resolving otitis media with effusion in children: An adaptive randomized-controlled trial protocol.

Evaluating the impact of the 'Blow, Breathe, Cough' health promotion intervention in resolving otitis media with effusion in children: An adaptive randomized-controlled trial protocol.

Journal: Contemporary clinical trials communications

Published: May 15, 2025

Acellular Pertussis Vaccine Given in the Week After Birth Does Not Impair Antibody Responses to Later Childhood Doses.

Acellular Pertussis Vaccine Given in the Week After Birth Does Not Impair Antibody Responses to Later Childhood Doses.

Journal: The Pediatric infectious disease journal

Published: March 10, 2025

Haemophilus influenzae remains the predominant otitis media pathogen in Australian children undergoing ventilation tube insertion in the PCV13 era.

Haemophilus influenzae remains the predominant otitis media pathogen in Australian children undergoing ventilation tube insertion in the PCV13 era.

Journal: The Journal of infection

Published: January 23, 2025

Immunogenicity and Safety of a 2 + 1 DTPa Priming Schedule in Australian Infants and the Impact of Maternally Derived Antibodies on Pertussis Antibody Responses up to 4 Years of Age.

Immunogenicity and Safety of a 2 + 1 DTPa Priming Schedule in Australian Infants and the Impact of Maternally Derived Antibodies on Pertussis Antibody Responses up to 4 Years of Age.

Journal: Journal of the Pediatric Infectious Diseases Society

Published: November 28, 2024

The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old.

The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old.

Journal: The Journal of infection

Published: August 20, 2024

The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old.

The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old.

Journal: The Journal of infection

Published: August 20, 2024

The Respiratory Microbiome in Paediatric Chronic Wet Cough: What Is Known and Future Directions.

The Respiratory Microbiome in Paediatric Chronic Wet Cough: What Is Known and Future Directions.

Journal: Journal of clinical medicine

Published: October 29, 2023

Showing 1-12 of 59

Last Updated: 09/26/2026